(Albany, USA) DelveInsight’s “Breast Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Breast Cancer, historical and forecasted epidemiology as well as the Breast Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Breast Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Breast Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Breast Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Breast Cancer market.
Request for a Free Sample Report @ Breast Cancer Market Forecast
Some facts of the Breast Cancer Market Report are:
- According to DelveInsight, Breast Cancer market size is expected to grow at a decent CAGR by 2032.
- Leading Breast Cancer companies working in the market are Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, DaiichiSankyo, Pfizer Inc., AstraZeneca, Novartis AG, Merck, Sanofi, Bristol-Myers Squibb, Eisai, Mylan N.V., Teva Pharmaceutical, Kyowa Kirin Co., Ltd., MacroGenics, Inc., Gilead Sciences, Takeda Pharmaceutical Company Limited, and AbbVie Inc. and others.
- Key Breast Cancer Therapies expected to launch in the market are Camizestrant (AZD9833), Lasofoxifene, IBRANCE (palbociclib), LYNPARZA (olaparib), and others.
- In November 2023, Pfizer announces that its new breast cancer drug, palbociclib, has been approved by the FDA for the treatment of patients with HER2-positive metastatic breast cancer. Palbociclib is a CDK4/6 inhibitor that works by blocking the growth and spread of cancer cells.Merck announces that its new breast cancer drug, pembrolizumab, has been approved by the FDA for the treatment of patients with triple-negative breast cancer (TNBC). Pembrolizumab is an immunotherapy drug that works by boosting the body’s immune system to fight cancer cells. Roche announces that its new breast cancer drug, tucatinib, has been approved by the FDA for the treatment of patients with HER2-positive advanced or metastatic breast cancer. Tucatinib is a TKI that works by blocking the HER2 protein, which is involved in the growth and spread of cancer cells.
Breast Cancer Overview
Breast cancer forms when cells in the breast mutate and grow uncontrollably. It is the most common cancer among women globally. While it primarily affects women, men can also develop breast cancer, though it’s rare. Risk factors include age, family history, genetic mutations (such as BRCA1 and BRCA2), hormonal factors (early menstruation, late menopause, hormone replacement therapy), obesity, alcohol consumption, and radiation exposure. Symptoms may include a lump in the breast, changes in breast size or shape, dimpling of the breast skin, nipple discharge, or nipple inversion. Diagnosis involves mammograms, ultrasounds, MRIs, and biopsies. Treatment options vary based on the stage and type of cancer but may include surgery, chemotherapy, radiation therapy, hormone therapy, targeted therapy, or a combination. Early detection through screening and advancements in treatment have significantly improved survival rates and quality of life for those with breast cancer.
Learn more about Breast Cancer treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Breast Cancer Treatment Market
Breast Cancer Market
The Breast Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Breast Cancer market trends by analyzing the impact of current Breast Cancer therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Breast Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Breast Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Breast Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.
Breast Cancer Epidemiology
The Breast Cancer epidemiology section provides insights into the historical and current Breast Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Breast Cancer market report also provides the diagnosed patient pool, trends, and assumptions.
Explore more about Breast Cancer Epidemiology @ Breast Cancer Incidence
Breast Cancer Drugs Uptake
This section focuses on the uptake rate of the potential Breast Cancer drugs recently launched in the Breast Cancer market or expected to be launched in 2019-2032. The analysis covers the Breast Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Breast Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Breast Cancer market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Breast Cancer Pipeline Development Activities
The Breast Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Breast Cancer key players involved in developing targeted therapeutics.
Request for a sample report to understand more about the Breast Cancer pipeline development activities @ Breast Cancer Therapies and Drugs
Breast Cancer Therapeutics Assessment
Major key companies are working proactively in the Breast Cancer Therapeutics market to develop novel therapies which will drive the Breast Cancer treatment markets in the upcoming years are Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, DaiichiSankyo, Pfizer Inc., AstraZeneca, Novartis AG, Merck, Sanofi, Bristol-Myers Squibb, Eisai, Mylan N.V., Teva Pharmaceutical, Kyowa Kirin Co., Ltd., MacroGenics, Inc., Gilead Sciences, Takeda Pharmaceutical Company Limited, and AbbVie Inc. and others.
Learn more about the emerging Breast Cancer therapies & key companies @ Breast Cancer Clinical Trials and FDA Approvals
Breast Cancer Report Key Insights
1. Breast Cancer Patient Population
2. Breast Cancer Market Size and Trends
3. Key Cross Competition in the Breast Cancer Market
4. Breast Cancer Market Dynamics (Key Drivers and Barriers)
5. Breast Cancer Market Opportunities
6. Breast Cancer Therapeutic Approaches
7. Breast Cancer Pipeline Analysis
8. Breast Cancer Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Breast Cancer Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Breast Cancer Competitive Intelligence Analysis
4. Breast Cancer Market Overview at a Glance
5. Breast Cancer Disease Background and Overview
6. Breast Cancer Patient Journey
7. Breast Cancer Epidemiology and Patient Population
8. Breast Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Breast Cancer Unmet Needs
10. Key Endpoints of Breast Cancer Treatment
11. Breast Cancer Marketed Products
12. Breast Cancer Emerging Therapies
13. Breast Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Breast Cancer Market Outlook (7 major markets)
16. Breast Cancer Access and Reimbursement Overview
17. KOL Views on the Breast Cancer Market
18. Breast Cancer Market Drivers
19. Breast Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage